- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01143194
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Effects of Three Doses of the Dietary Supplement oréVida™ on Alertness, Attention and Concentration in Healthy Men and Women
The purpose of this study is to investigate the effects of the dietary supplement oréVida™ (active ingredient on the basis of a culinary herb)administered twice daily in an acute study on an improvement in vigilance, attention, concentration, memory and mood in 45 healthy men and pre-menopausal women, aged 35-50 years, inclusive.
oréVida™ is considered a dietary supplement, and therefore it is not an approved drug by the Food and Drug Administration (FDA). It is regulated like a food. The U.S. Food and Drug Administration does not strictly regulate herbs and dietary supplements. We do not claim that this supplement is meant to treat any ailment.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Illinois
-
Addison, Illinois, Forenede Stater, 60101
- Provident Clinical Research
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Subject is a male or pre-menopausal female, 35-50 years, inclusive. Post-menopausal is defined as a history of spontaneous amenorrhea for a period of 12 consecutive months or six weeks post-surgical bilateral oophorectomy, with or without hysterectomy.
- Subject is willing to maintain his or her habitual diet and usual physical activity patterns throughout the study.
- Subject has no health conditions that would prevent him/her from fulfilling the study requirements as judged by the Investigator on the basis of medical history and routine laboratory test results.
- Subject has a body mass index (BMI) of ≥20.00 and <30.00 kg/m2
- Subject is willing to refrain from consuming alcohol 24 h prior to test days.
- Subject is willing to refrain from consuming caffeine and caffeine-containing products 12 h prior to test days.
- Subject is willing to refrain from vigorous physical activity 12 h prior to test days.
- Subject is a non-smoker.
- Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.
Exclusion Criteria:
- Subject has a positive drug screening of amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, methamphetamines, methadone, 3,4-methylenedioxymethamphetamine, opiates or tricyclic antidepressants at screening.
- Subject has abnormal laboratory test results of clinical significance, including, but not limited to: creatinine ≥1.5 mg/dL, or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥1.5X the upper limit of normal at screening.
- Subject has donated more than 300 mL of blood during the three months prior to screening.
- Subject has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg) as defined by the average blood pressure measured at screening. One re-test will be allowed on a separate day prior to visit 2, day 0 for subjects whose blood pressure exceeds either of these cut points at visit 1.
- Subject has a history or presence of clinically important cardiac, renal, hepatic, endocrine (including diabetes mellitus), pulmonary, biliary, gastrointestinal, pancreatic, or neurologic disorders that, in the judgment of the Investigator, would interfere with the subject's ability to provide informed consent, comply with the study protocol (which might confound the interpretation of the study results), or put the subject at undue risk.
- Subject has a history, in the judgment of the Investigator, of a psychological illness or condition such as to interfere with the subject's ability to understand the requirements of the study.
- Use of any sleep aid medication within four days prior to each test day.
- Subject has a history or presence of cancer in the prior two years, except for non-melanoma skin cancer.
- Subject is pregnant, planning to be pregnant during the study period, lactating, or women of childbearing potential who are unwilling to commit to the use of a medically approved form of contraception throughout the study period. The method of contraception must be recorded in the source documentation.
- Excessive habitual caffeine consumption (>300 mg caffeine/d or ≥3 cups of caffeinated coffee/d), following screening and throughout the study period.
- Use of any psychotropic medication within four weeks of screening and throughout the study.
- Use of antibiotics or signs of active systemic infection. Treatment visits will be rescheduled to allow the subject to wash off of the antibiotic for at least five days prior to any test visit.
- Subject has had exposure to any non-registered drug product within 30 days prior to the screening visit.
- Use of dietary supplements containing any of the following: ginkgo biloba, St. John's wort, ginseng, gotu kola (Indian pennywort); daily doses of vitamin E (≥30 mg/d) or folic acid (≥400 ug/d); thiamine, riboflavin, and/or pyridoxine (≥2 mg/d); and eicosapentaenoic acid (EPA), docosahexaenoic acid or a combination of EPA + DHA (≥500 mg/d) within 2 weeks of screening visit.
- Recent history of (within 12 months of screening visit 1) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as >14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1½ oz distilled spirits).
- Subject has a known allergy or sensitivity to study product or any ingredients of the study product or meals provided.
- The subject is unable to perform the tests on the CDR System during training to the established acceptable levels for participation in this type of study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Placebo komparator: Placebo
|
1 capsule of placebo twice a day
|
Eksperimentel: oréVida™ 60mg/day
|
1 capsule 30 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 60 mg/day)
1 capsule 60 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 120mg/day)
1 capsule 120 mg oréVida™ in the morning, one placebo capsule in the afternoon (si in total 120 mg/day)
|
Eksperimentel: oréVida™ 120mg/day (1)
|
1 capsule 30 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 60 mg/day)
1 capsule 60 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 120mg/day)
1 capsule 120 mg oréVida™ in the morning, one placebo capsule in the afternoon (si in total 120 mg/day)
|
Eksperimentel: oréVida™ 120mg/day (2)
|
1 capsule 30 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 60 mg/day)
1 capsule 60 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 120mg/day)
1 capsule 120 mg oréVida™ in the morning, one placebo capsule in the afternoon (si in total 120 mg/day)
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Vigilance, Attention, and Concentration Tasks
Tidsramme: 4 times one day (at each test day, tasks 13 times repeated)
|
Cognitive Drug Research (CDR) Test Battery Attention:
|
4 times one day (at each test day, tasks 13 times repeated)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Working Memory & Executive Function Tasks
Tidsramme: 4 times one day (at each test day, tasks 7 times repeated)
|
CDR Test Battery Memory:
|
4 times one day (at each test day, tasks 7 times repeated)
|
Episodic Secondary Memory Tasks
Tidsramme: 4 times one day (at each test day, tasks 7 times repeated)
|
CDR Test Battery Memory:
|
4 times one day (at each test day, tasks 7 times repeated)
|
Additional Measurements / Questionnaires
Tidsramme: 4 times one day (at each test day, VAS 13 times repeated / POMS 3 times repeated)
|
|
4 times one day (at each test day, VAS 13 times repeated / POMS 3 times repeated)
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Kathleen Kelley, MD, Provident Clinical Research
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- 2009-11-06-OREG
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Opmærksomhed
-
Virginia Commonwealth UniversityTrukket tilbageAttention Fatigue, Attention Restoration
-
Ornit CohenUkendtAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder med hyperaktivitet | Attention Deficit Disorder | Attention Deficit Disorders med hyperaktivitet | Attention Deficit Hyperactivity DisordersIsrael
-
Children's National Research InstituteRekrutteringADHD | Attention Deficit Hyperactivity Disorder | Attention-Deficit Hyperactivity Disorder | Attention Deficit Disorder | TILFØJE | ADHD Overvejende uopmærksom type | ADHD - kombineret type | ADHD, overvejende hyperaktiv - impulsiv | Attention-Deficit Disorder i ungdomsårene | Attention-Deficit Hyperactivity...Forenede Stater
-
Soroka University Medical CenterUkendt
-
Tel-Aviv Sourasky Medical CenterElMindA Ltd; Brainsway; Ornim Medical Ltd.UkendtAdult Attention Deficit DisorderIsrael
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)RekrutteringAttention-Deficit Hyperactivity DisorderForenede Stater
-
Ironshore Pharmaceuticals and Development, IncAfsluttetAttention-Deficit Hyperactivity DisorderForenede Stater
-
Florida International UniversityAfsluttetAttention-deficit/Hyperactivity DisorderForenede Stater
-
National Taiwan University HospitalUkendtAttention Deficit/Hyperactivity DisorderTaiwan
-
National Taiwan University HospitalAfsluttetAttention-deficit/Hyperactivity DisorderTaiwan
Kliniske forsøg med oréVida™
-
BaroNova, Inc.Afsluttet
-
London Health Sciences CentreUniversity of Western Ontario, Canada; Synaptive MedicalUkendtHjerneskade, kronisk | Cerebellar Cognitive Affective Syndrome | Cerebellar mutisme
-
Medtronic CardiovascularMedtronicAfsluttetAortastenoseNew Zealand, Det Forenede Kongerige, Australien
-
Gülçin Özalp GerçekerAfsluttetKateterkomplikationer | KateterlækageKalkun
-
CereVasc IncAlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting...RekrutteringHydrocephalus | Hydrocephalus, KommunikerendeArgentina
-
Asklepios Kliniken Hamburg GmbHUniversity of KielAfsluttetLuftvejsstyring | Larynx maske Airway | Fibreoptisk intubation
-
Medtronic CardiovascularAktiv, ikke rekrutterendeAortaaneurismeTyskland, New Zealand, Forenede Stater, Holland, Schweiz, Det Forenede Kongerige, Spanien, Australien, Italien, Sverige, Frankrig, Østrig, Slovakiet
-
Andrew ParrentUniversity of Western Ontario, Canada; Synaptive MedicalUkendtTemporallappepilepsi
-
GlaxoSmithKlineAfsluttetStivkrampe | Difteri | Acellulær Pertussis | Poliomyelitis | Haemophilus Influenzae Type bKorea, Republikken
-
GlaxoSmithKlineAfsluttetHepatitis B | Hepatitis ATyskland, Belgien, Tjekkiet